THOUSAND OAKS, Calif., Aug. 22, 2019 /PRNewswire/ — Amgen (AMGN) and Allergan plc. (AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798, a biosimilar candidate to Rituxan® (rituximab), compared to Rituxan in patients with CD20-positive B-cell non-Hodgkin’s lymphoma. The primary endpoint, an assessment of overall response rate (ORR) by week 28, was within the prespecified margin for ABP 798 compared to Rituxan, showing clinical equivalence.

source https://finance.yahoo.com/news/amgen-allergan-announce-positive-top-130000820.html?.tsrc=rss